Get the Stockscreener App
2.48
1.22%
0.03
After Hours:
2.53
0.05
+2.02%
Tharimmune Inc stock is traded at $2.48, with a volume of 75,038.
It is up +1.22% in the last 24 hours and down -8.82% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$2.45
Open:
$2.36
24h Volume:
75,038
Relative Volume:
2.02
Market Cap:
$2.78M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-3.4444
EPS:
-0.72
Net Cash Flow:
$-7.30M
1W Performance:
-10.87%
1M Performance:
-8.82%
6M Performance:
-61.57%
1Y Performance:
-17.33%
1-Day Range:
$2.36
$2.60
1-Week Range:
$2.2501
$2.87
52-Week Range:
$2.151
$71.85
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Tharimmune Inc Stock (THAR) Latest News
Tharimmune Announces Intent to Acquire Intract Pharma - TipRanks
Tharimmune signs nonbinding LOI to merge with Intract Pharma - TipRanks
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company - StockTitan
Hillstream Biopharma stock plunges to 52-week low of $2.52 - Investing.com India
Hillstream Biopharma stock plunges to 52-week low of $2.52 - Investing.com
Tharimmune Expands Immunology Pipeline with Intract License - TipRanks
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab - StockTitan
Tharimmune, Inc. (NASDAQ:THAR) Short Interest Down 35.7% in July - Defense World
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory BoardChannel3000.com - Channel3000.com - WISC-TV3
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board - StockTitan
Tharimmune adds David Clarke as Strategic Advisor - Investing.com
Tharimmune launches new website amid continuing discussions wtih FDA - TipRanks
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor - StockTitan
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104 - StockTitan
Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update - Defense World
Tharimmune names industry veteran Haimovitz as strategic advisor - Investing.com
Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor - StockTitan
Tharimmune raises $2.08 million in private placement By Investing.com - Investing.com Australia
Tharimmune to sell 659,545 shares at $3.16 in private placementTipRanks.com - TipRanks
Tharimmune raises $2.08 million in private placement - Investing.com India
Tharimmune raises $2.08 million in private placement By Investing.com - Investing.com
Tharimmune raises $2.08 million in private placement By Investing.com - Investing.com UK
Tharimmune Announces $2.08 Million Private Placement | THAR Stock News - StockTitan
Tharimmune Announces $2.08 Million Private Placement - StockTitan
Tharimmune announces Type C meeting with FDA for Phase 2 TH104 programTipRanks.com - TipRanks
THAR: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
FDA nods to Tharimmune's Phase 2 itch relief trial plan By Investing.com - Investing.com
FDA nods to Tharimmune's Phase 2 itch relief trial plan - Investing.com India
FDA nods to Tharimmune's Phase 2 itch relief trial plan - Investing.com South Africa
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for ... - StockTitan
FDA nods to Tharimmune's Phase 2 itch relief trial plan - Investing.com
Tharimmune announces results of Phase 1 trial of TH104TipRanks.com - TipRanks
Tharimmune (THAR) Reports Positive Results of Phase 1 Trial in Healthy Subjects with TH104 - StreetInsider.com
Why Tharimmune (THAR) Shares Are Getting Hammered - MSN
Tharimmune reports promising Phase 1 results for TH104 By Investing.com - Investing.com Canada
Tharimmune reports promising Phase 1 results for TH104 By Investing.com - Investing.com
Why Tharimmune (THAR) Shares Are Getting HammeredTharimmune (NASDAQ:THAR) - Benzinga
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for ... - Yahoo Finance
Why Tharimmune (THAR) Shares Are Getting Hammered - Benzinga
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.55% - MSN
Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Drops By 83.2% - MarketBeat
Investor's Toolkit: Key Ratios for Assessing Tharimmune Inc (THAR)'s Performance – DWinneX - The Dwinnex
Why Is Tharimmune (THAR) Stock Moving Today? - MSN
Prepare Yourself for Liftoff: Tharimmune Inc (THAR) – Sete News - SETE News
Why Is Tharimmune (THAR) Stock Moving Today? - InvestorPlace
Tharimmune Stock Set to Reverse Split on Tuesday, May 28th (NASDAQ:THAR) - Defense World
Tharimmune announces 1-for-15 reverse stock splitTipRanks.com - TipRanks
Upward Trajectory: Tharimmune Inc (THAR) Posts a Slidee, Closing at 0.33 – DWinneX - The Dwinnex
Tharimmune Inc (THAR) Stock: A Year of Decreases and Increases - The InvestChronicle
Tharimmune announces 1-for-15 reverse stock split By Investing.com - Investing.com
Tharimmune announces 1-for-15 reverse stock split By Investing.com - Investing.com UK
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):